Table 1 Baseline characteristics in total and sub-group patients
Characteristics | Total | Insulin-naïve group* | Insulin non-naïve group† | |
|---|---|---|---|---|
N | 4219 | 3732 | 487 | |
Male | Missing data | 1 | 1 | 0 |
n (%) | 2485 (58.9) | 2237 (59.9) | 248 (50.9) | |
Age (years) | Missing data | 8 | 8 | 0 |
Mean ± SD | 62.8 ± 12.1 | 62.6 ± 12.1 | 64.0 ± 12.1 | |
Weight (kg) | Mean ± SD | 61.7 ± 11.6 | 61.8 ± 11.7 | 61.0 ± 11.5 |
BMI (kg/m2) | Mean ± SD | 23.8 ± 3.3 | 23.7 ± 3.3 | 24.0 ± 3.3 |
Duration of diabetes, years, n (%) | Missing data | 241 (5.7) | 221 (5.9) | 20 (4.1) |
<1 | 50 (1.2) | 46 (1.2) | 4 0.8) | |
≥1, <5 | 466 (11.0) | 436 (11.7) | 30 (6.2) | |
≥5 | 3462 (82.1) | 3029 (81.2) | 433 (88.9) | |
OADs prescribed before study, n (%) | 1 | 975 (23.1) | 757 (20.3) | 218 (44.8) |
2 | 1719 (40.7) | 1537 (41.2) | 182 (37.4) | |
3 | 1189 (28.2) | 1114 (29.8) | 75 (15.4) | |
≥4 | 336 (8.0) | 324 (8.7) | 12 (2.5) | |
Types of OADs prescribed before study, n (%) | BG | 1991 (47.2) | 1782 (47.7) | 209 (42.9) |
SU | 3587 (85.0) | 3316 (88.9) | 271 (55.6) | |
Glinides | 312 (7.4) | 269 (7.2) | 43 (8.8) | |
α-GI | 1971 (46.7) | 1717 (46.0) | 254 (52.2) | |
TZD | 1360 (32.2) | 1287 (34.5) | 73 (15.0) | |
Diabetic complications | Neuropathy | 1083 (25.7) | 933 (25.0) | 150 (30.8) |
Retinopathy | 1148 (27.2) | 971 (26.0) | 177 (36.3) | |
Nephropathy | 1121 (26.6) | 953 (25.5) | 168 (34.5) | |
eGFR (mL/min/1.73 m2) | Missing data | 997 (23.6) | 892 (23.9) | 105 (21.6) |
≥90 | 1030 (24.4) | 933 (25.0) | 97 (19.9) | |
≥60, <90 | 1558 (36.9) | 1375 (36.8) | 183 (37.6) | |
<60 | 634 (15.0) | 532 (14.3) | 102 (20.9) | |